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Chlamydia trachomatis (chlamydia) is a sexually transmitted infection that is usually 
asymptomatic but can result in serious reproductive sequelae if left untreated. Screening and 
treating sexually active young adults for chlamydia helps prevent transmission and reduces 
incidence and prevalence. Monitoring prevalence and case rate trends through surveillance is 
important for assessing screening effectiveness. However, trends from surveillance data are 
difficult to interpret because they are influenced by important time-varying biases. The purpose 
of this dissertation was to 1) estimate chlamydia prevalence trends among a sentinel population 
of young adults, accounting for bias from changing risk profiles (case mix) and imperfect 
screening tests, and 2) estimate the annual incidence rate of correctly diagnosed chlamydia that 
would be obtained with perfect screening coverage, screening tests, and case reporting. 
 For the first objective, we estimated prevalence among young women and men entering 
the National Job Training Program from 1990 through 2012. We examined the distribution of 
enrollment by race/ethnicity and region over time to assess case mix, and corrected for time-
varying measurement error introduced by increasingly sensitive screening tests. For the second 
objective, we estimated bias due to screening coverage, screening tests, and reporting, and 
corrected annual chlamydia case rates from 2000 through 2015 among young women using a 
series of corrections.  
 Chlamydia prevalence trends among high-risk young women declined from 20% in 1990 
to 12% in 2003, and were relatively stable from 2004 through 2012. Trends among men were 
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stable over the course of the study at approximately 7%. Prevalence was highest among Black 
women and men, and in the Southern and Midwestern regions of the US. Counterfactual 
incidence rates of correctly diagnosed chlamydia among young women were higher than 
reported case rates, and declined from 12,900 cases per 100,000 person-years in 2000 to 7,100 
cases per 100,000 person-years in 2015. Trends declined sharply from 2000 through 2007, and 
modestly from 2008 through 2015. 
 Declining chlamydia prevalence and counterfactual incidence rate trends suggest that 
screening programs may have initially been effective at reducing chlamydia burden, but 
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CHAPTER ONE: SPECIFIC AIMS 
 Chlamydia is the most commonly reported sexually transmitted infection (STI) in the 
US.(1) Since prevalence is highest among young adults age 15 through 24 and infections are 
often asymptomatic, screening young, sexually active individuals to detect and treat disease is 
important for reducing the risk of reproductive sequelae.(1–7) Untreated infections may lead to 
pelvic inflammatory disease, infertility, and ectopic pregnancy in women, and urethritis, 
prostatitis and infertility in men.(1,6,8–12) Given the severity of sequelae that may result from 
undetected and untreated infections, federally funded, national screening programs were 
introduced in the late 1980s with the public health goal of reducing disease prevalence, 
transmission, and incidence.(13) Monitoring chlamydia prevalence and reported case rate 
trends using surveillance data is critically important for helping to determine whether large-scale 
screening programs have been effective in reaching program goals.  
 
 Interpreting long-term chlamydia prevalence and case rate trends from surveillance data 
is challenging because trends can be influenced by multiple biases. Prevalence trends are 
derived from sentinel surveillance of populations that have universal screening coverage, and 
are calculated by dividing the number of cases by the total population screened. Case rates 
trends are derived from population-based surveillance and serve as proxies for incidence rates. 
Case rates are calculated by dividing the number of nationally reported cases by person time at 
risk during one year, which is estimated from census data. Both prevalence estimates and case 
rate estimates are influenced by the use of increasingly sensitive screening tests over time, and 
by changes in case mix (the proportion of high and low-risk individuals screened in a 
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population).(1,14–16) Case rates are also influenced by changes in screening coverage (the 
proportion of the population that is screened) and changes in case reporting compliance (the 
proportion of cases reported).(1,14,15) These biases may mask the true population prevalence 
and case rate. 
 
 Prevalence and case rate trends that do not properly account for biases may be 
misleading. Observed chlamydia prevalence trends over the last two decades from sentinel 
surveillance among the National Job Training Program (NJTP), a national vocational training 
program for youth, are modestly decreasing, suggesting that screening may have been effective 
at reducing disease burden.(17–22) But these trends do not sufficiently account for time-varying 
case mix and measurement error associated with changes in screening tests, and may not 
reflect true prevalence trends. National chlamydia case rates are also difficult to interpret. 
Reported case rates have generally been increasing over the past two decades, suggesting that 
screening has not been effective.(1) However, these rates are influenced by the use of 
increasingly sensitive screening tests, case mix, expanded screening coverage, and improved 
reporting compliance. To accurately assess the effectiveness of screening programs on a 
population level using surveillance data, the effects of multiple biases on prevalence and case 
rate estimates must be considered.  
 
 The goals of the proposed study are to 1) produce less biased chlamydia prevalence 
trends among a sentinel surveillance population over the past two decades and 2) examine how 
increased screening coverage, more sensitive screening tests, case mix and improved reporting 
influence reported national chlamydia case rates. The specific aims of this proposal are to:  
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Aim 1: Estimate long-term trends of chlamydia prevalence among a national sample of 
young adults, accounting for time-varying measurement error associated with changes in 
screening test use and bias due to case mix.  
 
Aim 2: Estimate counterfactual incidence rates of correctly diagnosed chlamydia among 
young women from 2000 through 2015, accounting for changes in screening coverage, 
screening tests, case mix, and reporting compliance, and compare counterfactual 
incidence rates to reported case rates.  
 
 To address aim 1, we used annual cross-sectional chlamydia screening data from young 
adults entering the NJTP collected from 1990-2012. The NJTP is an ideal data source for this 
research because all NJTP entrants are screened for chlamydia and characteristics of NJTP 
enrollees have remained relatively stable over time, so prevalence can be easily measured. To 
address aim 2, we triangulated estimates of biases over time by reviewing published literature 
and consulting expert opinion. Through a series of corrections that account for multiple biases, 
we estimated counterfactual incidence rates of correctly diagnosed chlamydia that would be 
obtained with perfect screening coverage, screening tests, and reporting.  
 
 This research produced minimally biased, long-term chlamydia prevalence trends, and 
demonstrated how reported chlamydia case rates are influenced by multiple biases. These 
analyses helped us understand whether the national screening efforts implemented over the 
past two decades have been effective at reducing disease burden. In addition, this research 
enabled us to more accurately and meaningfully interpret national chlamydia case rate trends.
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
 Chlamydia trachomatis (chlamydia) is the most commonly reported STIs in the US.(1) 
Approximately 1.5 million cases of chlamydia were reported in the US in 2016, and the burden 
of infection is highest among young adults age 15 to 24 years, non-Hispanic Blacks, and the 
Southern region of the US.(1) Most infections are asymptomatic and untreated infections can 
lead to serious reproductive sequelae, including pelvic inflammatory disease (PID), infertility, 
and ectopic pregnancy in women, and urethritis, prostatitis, and infertility in men.(1,6,11,12) 
Untreated infections may also facilitate transmission of HIV.(23,24) Chlamydia can usually be 
treated easily with antibiotics.(2) Given the high case reporting and clinical features of 
chlamydia, regular screening of sexually active people to detect and treat infections is important 
from both an individual and population level perspective. On an individual level, screening 
allows for detection and treatment of infected individuals, which can reduce their risk of 
reproductive sequelae.(15,25) On a population level, screening and treating infected individuals 
may reduce prevalence, which can in turn reduce transmission and incidence.(6,25–27)  
 
 Large-scale screening programs for chlamydia have been in place in the US for over 20 
years, and evaluating the effectiveness of these screening programs is an important part of 
gauging return on investment. National chlamydia screening programs were first supported by 
the Centers for Disease Control and Prevention in the late 1980s, and federally funded national 
screening was introduced in the 1990s as part of the Infertility Prevention Project (IPP).(13) 
These programs aimed to increase access to chlamydia screening and treatment services for 
low-income, sexually active women attending public clinics. Ideally, the effectiveness of these 
screening programs would be assessed from both individual and population level perspectives. 
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On an individual level, successful screening programs would result in reduced incidence of PID, 
infertility, and ectopic pregnancy. However, since reproductive sequelae caused by chlamydia 
also have other etiologies and are inconsistently reported, evaluating the success of screening 
programs by monitoring incidence of these sequelae has been challenging.(6,26) On a 
population level, screening program effectiveness would be indicated by a decline in chlamydia 
prevalence and incidence over time.  
 
 True chlamydia prevalence and incidence on a national scale are difficult to measure, so 
prevalence estimates are derived from sentinel surveillance or population surveys, and 
incidence is represented by rates of reported cases from population-based surveillance. 
Specifically, prevalence can be estimated from sentinel populations with universal screening, 
such as NJTP(17–22) or military.(28–30) Estimates can also be derived from national 
population-based surveys such as the National Health and Nutrition Examination Survey 
(NHANES)(1,3–5) or the National Longitudinal Study of Adolescent to Adult Health (Add 
Health), although these estimates can be difficult to ascertain given the expense and 
implementation challenges of large survey studies(1,7) Case rates act as a proxy for incidence 
rates, and are derived from national population-based surveillance. Annual case rates are 
calculated from the total number of reported cases in a year (the numerator in the case rate) 
and person time in one year, which is total number of people in a population, gathered from 
census data, multiplied by one year (the denominator in a case rate).(15) Trends in prevalence 
and case rates from surveillance data can be used to evaluate screening programs on a 
population level. 
 
 However, prevalence and case rate trends from surveillance data should be interpreted 
carefully because both measures can be influenced by biases that can mask true changes in 
prevalence or case rates. Prevalence and case rates are affected by several biases that 
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influence the numerators of these measures.(14,15) Both prevalence and case rates are 
influenced by time-varying case mix (i.e., the relative proportion of high and low risk individuals 
in a population) and measurement error associated with using increasingly sensitive screening 
tests over time. Case rates are additionally influenced by screening coverage and reporting 
practices.  
 
 The concept of case mix refers to the relative distribution of high and low risk individuals 
who are screened in a population, and changes in case mix can bias prevalence and case rate 
measures by causing the numerator to change while the denominator remains constant.(6) For 
example, in a population with high and low risk individuals, many cases will be detected if a 
large proportion of high-risk individuals is screened. If, over time, fewer high-risk individuals are 
screened and more low-risk individuals are screened, fewer cases will be detected. In this 
scenario, the number of cases that are identified through screening declines as the composition 
of high and low-risk individuals being screened changes. The change in the relative proportion 
of risk levels of individuals being screened does not necessarily reflect true changes in the 
underlying population disease burden. Changes in case mix over time may produce an artificial 
increase or decrease in prevalence or case rates. Although difficult to measure, case mix is 
important to consider when interpreting disease trends.  
 
 Changes in screening test can also bias prevalence and case rates, and should be 
considered jointly with case mix. As screening test technologies improve, tests become better at 
detecting cases of chlamydia. While all screening tests introduce some measurement error due 
to imperfect sensitivity (the probability of testing positive given disease is present) and 
specificity (the probability of testing negative given disease is absent), new technologies 
typically have improved sensitivity and specificity. For chlamydia in particular, specificity of tests 
has always been high, but sensitivity has improved dramatically with new technologies. With 
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improved sensitivity, more cases are detected. But increased case detection due to better 
screening tests is not necessarily reflective of an increase in the true population disease 
prevalence.(15,16) Like case mix, changes in screening tests may inflate the numerators of a 
prevalence or case rate, while the denominators remain constant. Since case counts can be 
influenced by both case mix and measurement error associated with changes in screening 
tests, both biases should be accounted for when analyzing and interpreting prevalence and 
case rate trends.  
 
 Case rates are influenced by two additional biases: reporting bias and screening 
coverage. Reporting bias refers to changes the proportion of cases that are detected and 
reported through passive surveillance. Chlamydia has been nationally notifiable conditions since 
1994, and has been reported by all 50 states and the District of Columbia since 2000. Reporting 
is imperfect, but has improved due electronic laboratory reporting systems, which enable cases 
to be reported directly from laboratories and do not rely on physicians’ reporting compliance. 
Electronic systems have become increasingly common since the early 2000s.(1,14) Improved 
reporting can contribute to the numerator of a case rate, but may not represent a true increase 
in the caseload. Similarly, screening coverage, or the proportion of the population that is 
screened, has expanded over time. When a larger proportion of the population is screened, 
more cases will be detected (contributing to the numerator of a rate). However, the denominator 
(total person time at risk) is not affected by changes in screening coverage.(15) Interpretation of 
case rates is exceedingly difficult because rates are influenced not only by changes in 
incidence, but also by multiple sources of bias. 
 
 Because prevalence trends are influenced by fewer biases than rates, prevalence is 
preferable for examining chlamydia trends over time. One of the most common sources for 
monitoring chlamydia prevalence trends is the NJTP. The NJTP is administered by the 
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Department of Labor, and is a no-cost, residential educational and vocational training program 
for socioeconomically disadvantaged youth between 16 through 24 years old. The Department 
of Labor began screening NJTP entrants for chlamydia in 1990. Since characteristics of NJTP 
entrants have remained stable over time and screening coverage is high, it is an optimal data 
source for measuring prevalence trends. Generally, the annual prevalence of both infections 
has been high, and modestly decreasing over time. Chlamydia prevalence among women fell 
from 14.9% to 10.0% from 1990 through 1997(22) and from 11.7% to 10.3% from 1998 through 
2004.(17) More recent estimates from 2006 through 2008 showed small declines in annual 
chlamydia prevalence among women who provided cervical and urine samples for screening 
(cervical: 16.0% to 15.0%, urine: 13.8% to 11.8% respectively).(19)  
 
 While modest decreases in chlamydia prevalence have been reported among NJTP 
entrants, these trends have two major limitations. First, the trends are short-term and span a 
maximum of seven years. Some trends are estimated for time periods during which only one 
screening test was used in order to avoid bias due to changing screening tests.(17,19,22) 
However, this prohibits direct comparisons of trends across time periods during which different 
screening tests were used; thus long-term trends cannot be assessed. In addition, a longer time 
period may be required to observe the effects of screening on annual prevalence trends. 
Second, trends that span periods when multiple tests were used do not properly account for 
measurement error associated with changing screening tests.(18,20,21) Estimates incorrectly 
account for changing screening tests by adjusting for test type in a generalized linear model. 
Including test type as a covariate in a model holds the effect of test type constant, but does not 
account for measurement error due to different test sensitivities and specificities.(15) Although 
some trends do account for case mix by examining the distribution of population characteristics 
over time, both case mix and changes in screening tests must be properly incorporated into 
analyses to produce valid, long-term prevalence trends.  
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 Finally, although case rates are influenced by more biases than prevalence, rates are 
still important to examine. Rates are conveniently and easily derived from national case report 
data and census data, and can be useful for describing chlamydia epidemiology on a national 
scale. As discussed earlier, several biases influence reported case rates, and the influence of 
biases can be clearly seen in national chlamydia case rate trends. National chlamydia case 
rates reported by the CDC have been generally increasing from 2000 through 2010 overall and 
among young women age 15 through 24 years, suggesting that disease burden is also 
growing.(1,31) However, during this same time period, use of more sensitive screening tests 
became increasingly common, screening coverage generally expanded, and reporting 
compliance among states and clinics improved.(1) Additionally, as screening became more 
accessible and was offered routinely in both private and public clinics, the proportion of high and 
low-risk individuals being screened likely fluctuated over time. The upward trend in chlamydia 
case rates has been attributed to expanded screening coverage and transitioning to screening 
test with near perfect sensitivity and specificity, but the effects of multiple biases on national 
rates have not been rigorously examined.(1,14,16,27,32) From 2010 through 2013, case rates 
began to decline, but it is unknown if the decline is due to changes in screening coverage or to a 
true decline in incidence.(1) Disentangling the effect of multiple biases on observed population 
chlamydia case rates is important for better understanding true population rates and the 
effectiveness of screening programs. 
 
  The goals of this research were to generate minimally biased chlamydia prevalence 
trends over the past two decades, and to examine the influence of multiple time-varying biases 
on national chlamydia case rates. First, this research generated valid chlamydia prevalence 
trends among NJTP entrants over the past 20 years, accounting for measurement error 
associated with changing screening tests and bias due to case mix. Understanding whether 
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prevalence of chlamydia is truly decreasing and quantifying changes in prevalence over time is 
important for understanding whether screening efforts over the past two decades have achieved 
their goal of reducing population disease burden. Second, this research examined how 
screening- and reported-related biases influence chlamydia case rates. By estimating 
counterfactual incidence rates of correctly diagnosed, we were able to assess the extent to 
which biases influence and limit interpretability of case rate trends. 
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CHAPTER THREE: RESEARCH DESIGN AND METHODS 
 
3.1 SPECIFIC AIM 1 
Estimate long-term trends of chlamydia prevalence among a national sample of young adults, 
accounting for time-varying measurement error associated with changes in screening test use 
and bias due to case mix.  
 
Specific Aim 1 Study Description 
 
Description of NJTP Population 
 We analyzed annual cross-sectional chlamydia screening data from young women and 
men enrolled in the NJTP from 1990 through 2012. The NJTP is a national educational and 
vocational training program for economically disadvantaged youths administered by the 
Department of Labor (33,34). Approximately 20,000 to 60,000 young adults are trained annually 
at residential centers nationwide. Men and women age 16 through 24 are eligible to enroll in the 
NJTP if they are legal US residents, meet low-income criteria, and face barriers to employment, 
such as needing additional training or education required to get and hold a job. Eligibility criteria 
for NJTP were consistent throughout the study period.  
 
 All NJTP enrollees are required to have a physical exam and STI screening within 48 
hours of entering the NJTP. Chlamydia screening has been required of all women since 1990, 
and of all men since 2003. Biological samples for screening were collected at NJTP center 
health services departments. Samples were collected either by a healthcare provider (cervical 
 
 12 
swabs) or self-collected (vaginal swabs or urine). Most NJTP sites sent samples for chlamydia 
testing to one national contract laboratory. The national contract laboratory reports the sample 
type, screening test type, and the screening test results (positive or negative) to the CDC 
Division of STD Prevention.  
 
Outcome Assessment  
 The outcome of interest for Aim 1 was laboratory-confirmed chlamydial infection. Several 
screening tests were used to identify a positive chlamydia case throughout the study period. 
From 1990 through 1997, chlamydia screening was performed via Pathfinder Enzyme 
Immunoassays (EIA) (Sanofi Diagnostics Pasteur, Inc, Redmond, Washington) of cervical 
specimens. From March 2000 through 2006, the Gen-Probe Pace2 assay (Gen-Probe Inc., San 
Diego, California), a DNA hybridization probe test, of cervical swabs (women) or urine samples 
(men) was used. From 2000 through 2012, BD ProbeTec ET test (Becton-Dickinson, Sparks, 
Maryland), a strand displacement assay test (nucleic acid amplification test NAAT) was used. 
From March 2000 through 2006, only urine (men and women) was screened with BD ProbeTec 
ET. After 2006, both urine and cervical or vaginal swabs were screened with BD ProbeTec ET. 
The screening test used from 1998 through February 2000 was not recorded. Since missing 
data were only associated with study year, test type during this period could not be imputed and 
was considered missing. 
 
Covariates 
 We included several demographic variables in our analyses. Variables included sex, 
age, race/ethnicity (self-reported non-Hispanic, Black, Hispanic, Native American), region of 
residence (Northeast, Midwest, South and West), and self-report of any STI symptoms at the 





 Eligible participants for these analyses were defined as non-Hispanic White, Black, 
Hispanic, or American Indian women and men entering the NJTP from 1990 through 2012 who 
had a positive or negative chlamydia screening test result. Enrollees were excluded if their 
chlamydia test result, race/ethnicity, region of residence at the time of enrollment, or type of 
chlamydia screening test were unknown or missing.  
 
 
Specific Aim 1 Analysis 
 
Meta-Analyses for Screening Test Sensitivity and Specificity 
 Sensitivity and specificity of screening tests vary by population, and the precise 
sensitivity and specificity for the NJTP population is unknown. To generate estimates for the 
NJTP population, we conducted a targeted meta-analysis of peer-reviewed literature to 
generate sensitivity and specificity estimates for the different tests used for screening of NJTP 
enrollees. Inclusion and exclusion criteria of peer-reviewed publications and assessment of 
publication validity were guided by the Quality Assessment of Studies of Diagnostic Accuracy 
tool.(35) Only studies that evaluated the same brand of chlamydia screening tests as those 
used for NJTP screening were considered. 
 
The following data were abstracted: 
• Study characteristics: First author’s name, year of publication, journal, study period, 
study design 
• Study sample characteristics: age, sex, race/ethnicity, geography, place of recruitment 
and screening, sample size 
• Screening tests data: number of true positives, true negatives, false positives, and false 




 Bivariate generalized linear mixed effects models with a logit link were used to calculate 
summary sensitivity and specificity estimates and corresponding 95% confidence intervals.  
 
Case Mix Assessment 
 We evaluated case mix by examining the distribution of enrollment by race/ethnicity 
(non-Hispanic White, Black, Hispanic, and American Indian) and enrollment by region (Midwest, 
South, Northeast, and West) for women and men throughout the study period. Race/ethnicity 
and region served as proxies for chlamydia risk since the prevalence and case rates of 
chlamydial infection vary by race/ethnicity and region, with Blacks and the Southern region of 
the US having the highest burden (1,4,7). We visualized the distribution of race and region over 
time using stacked bar charts and modeled enrollment using logistic regression. In all models, 
race/ethnicity or region was the dependent variable. Various functional forms of study year 
(continuous) were included as the independent variable(s). Akaike information criteria (AIC) and 
visual inspection were used to determine model fit.  
 
Modeling Chlamydia Prevalence 
 To account for time-varying measurement error associated with changing screening 
tests, the annual prevalence of chlamydia was modeled using an expectation maximization 
(EM) algorithm based maximum likelihood approach first described by Magder and Hughes 
(1997).(36) This approach uses EM to estimate a maximum-likelihood regression model when 
the outcome is measured with imperfect sensitivity and specificity, and allows the sensitivity and 
specificity of disease classification to vary across observations.  
 
 This approach incorporates a correction for outcome misclassification into logistic 
regression. First, using arbitrary regression parameters and Bayes theorem, the predicted 
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probability of being truly diseased for each observation is calculated based on the probability of 
being classified as diseased (the probability of a true positive or a false negative) given 
screening test sensitivity and specificity, and covariate values. The data are then duplicated and 
each observation included twice, once with the outcome variable set as diseased and another 
with the outcome set as non-diseased. A weighted logistic regression model is fitted with 
weights equal to the probability of being truly diseased and probability of being truly not 
diseased, respectively. The new regression parameters from the weighted logistic regression 
are then used to calculate new probabilities of being truly diseased. This process continues until 
convergence. The algorithm can be implemented using the LogitEM command in Stata. 
 
 Our models accounted for sensitivity and specificity estimates that were generated from 
our meta-analyses. Laboratory-confirmed chlamydial infection (positive or negative screening 
test result) was the dependent variable in all models and study year (continuous) was the 
independent variable. The functional form of year was assessed using AIC and visual 
inspection. Estimated coefficients from the model output (i.e. px= 1/(1+(e^-(βo+ β1X1) were used 
to calculate the predicted probability (prevalence) of chlamydia across study years. Ninety-five 
percent CIs were obtained by bootstrapping (n=200). Prevalence trends were modeled 
separately for women and men. We also stratified by race/ethnicity and region to examine 
differences in trends for each subgroup. 
 
Sensitivity Analyses  
 We conducted two sensitivity analyses to examine uncertainty around sensitivity and 
specificity estimates that were used to model prevalence. To account for random error, we 
modeled prevalence trends using the upper and lower bounds of the 95% CI around sensitivity 
and specificity estimates. To account for systematic error, we re-estimated test sensitivity and 
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specificity using more selective inclusion/exclusion criteria for the meta-analyses. We used 
these new estimates to model adjusted prevalence trends.  
 
Limitations 
 This research has several limitations. First, although the NJTP is a national sample of 
young adults, chlamydia trends are only generalizable to socio-economically disadvantaged 
young adults entering a job-training program. Trends may not reflect disease trends of young 
adults on a broader national scale. However, prevalence estimates of chlamydia from this 
population are still relevant and important because NJTP is comprised of individuals who are at 
typically highest risk of chlamydia and likely targets of screening programs. 
 
 Second, trends may be biased due to case mix and population characteristics that 
cannot be accounted for with the measured variables. This analysis used the best available 
covariates to represent case mix (race/ethnicity and residence). However, these variables may 
not fully capture changing risk profiles or characteristics of the NJTP population over time.  
 
 Third, we could not account for other factors, such as sexual behaviors, condom use, or 











3.2 SPECIFIC AIM 2: 
Estimate counterfactual incidence rates of correctly diagnosed chlamydia among young women 
from 2000 through 2015, accounting for changes in screening coverage, screening tests, case 
mix, and reporting compliance, and compare counterfactual incidence rates to reported case 
rates.  
 
Specific Aim 2 Study Description 
 
Conceptual Framework 
 Our estimation approach was based on a conceptual diagram of relationship between 
the at-risk population and surveillance-related biases. In our conceptualization, the true 
chlamydia caseload is systematically reduced by these biases. We start with a dynamic 
population of at-risk women in steady-state. Within this population are true chlamydia cases, as 
well as the proportion of the population that is screened for chlamydia, the proportion diagnosed 
with chlamydia, and the proportion reported as chlamydia cases. Reported chlamydia cases are 
an underestimate of true chlamydia cases in the population as a result of partial screening 
coverage, misclassification due to imperfect screening tests, and under-reporting.  
  
 We implemented a series of corrections that addressed each bias successively, and 
calculated the counterfactual incidence of correctly diagnosed chlamydia that would have been 
observed in the absence of screening- and reporting-related biases. Specifically, we corrected 
annual case rates for under-reporting, case misclassification, and partial screening coverage. 
We corrected case rates among all women aged 15 through 24, and stratified case rates by age 
group (15 through 19 years, and 20 through 24 years) to examine variation in trends among 
younger and older women. Our approach allowed for temporal variation in biases to reflect 




Description of National Chlamydia Case Rates 
 Reported chlamydia case rates for women in our target age groups (ages 15 through 24, 
15 through 19, and 20 through 24) in the US from 2000 through 2015 were obtained from the 
CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention AtlasPlus tool 
(37). Case rate numerators represent the total number of chlamydia cases (diagnoses) reported 
to the CDC in one year by STI control programs and health departments in all 50 states and the 
District of Columbia. Case rate denominators are calculated as the US census population of 
women of the target ages in a given year.  
 
 
Specific Aim 2 Analysis 
 
 We made a series of simple corrections to annual reported chlamydia case rates to 
account for under-reporting, imperfect screening tests, and partial screening coverage.  
 
For a given year, we defined the following: 
C = number of reported cases (case rate numerator) 
N = total at-risk population (case rate denominator) 
R = proportion of chlamydia diagnoses that were reported to CDC through national 
notifiable disease surveillance (reporting fraction)  
Se= screening test sensitivity 
Sp = screening test specificity 




 In each study year, we took 200 random draws from distributions describing reporting, 
screening tests, and screening coverage (see “Bias Parameter Inputs” below) to define values 
for the inputs R, Se, Sp, and Sc above. With the values in each draw, we performed the 
calculations described below to estimate the counterfactual incidence of correctly diagnosed 
chlamydia in a given year. We then compared the annual medians of these corrected rates to 
the reported chlamydia case rates from 2000 through 2015 to assess the impact of these biases 
on reported trends. 
 
Correcting for under-reporting 
 To correct for under-reporting of chlamydia cases, we divided reported chlamydia cases 
[C] by the reporting fraction [R]. This step generated the counterfactual count of chlamydia 
diagnoses (both true and false positives) among women screened that we would expect to be 
included in case rate estimates under perfect reporting. 
 
Correcting for misclassification due to imperfect screening tests 
 To calculate the number of true chlamydia cases among women who were screened in a 
given year, which we will call A, we corrected for misclassification of chlamydia cases due to 
imperfect screening test sensitivity and specificity following Greenland,1996 (38),  
  





where FrT is the number of false positive diagnoses per unit person-time among women 
screened. If we assume that each individual in a given annual case rate denominator (N) 
contributes, on average, one year of person time during which he or she is at risk of chlamydia 
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where P is the underlying true prevalence of chlamydia in the screened population. This 
assumption is valid if 1) the at-risk population is dynamic and in steady-state (39), 2) person-
time contributed by unidentified true cases is relatively small, and 3) identified cases are treated 
and promptly return to the pool of at-risk women.  
 
 We derived annual prevalence as follows: In a steady-state population with non-
differential screening according to true chlamydial infection, the cumulative number of 
diagnosed cases among women screened [C/R] in a given year should equal the number of 
new diagnoses that would be observed in a one-time screening process conducted in the 
population that year. This number, in turn, is equal to the total number of true and false positives 
that would be observed in that screening process, which can be calculated as !"#(!"# +







Substituting this expression for prevalence into Equation 2 above allowed us to calculate FrT, 
which we entered into Equation 1 to generate the counterfactual number of diagnosed true 
chlamydia cases that would have been observed among women screened under perfect 








Correcting for partial screening coverage 
 To correct for screening coverage, we divided the number of diagnoses of true 
chlamydia cases among women screened [A] by the screening coverage [Sc]. This step gave us 
the counterfactual number of correctly diagnosed chlamydia cases in the total at-risk population 
over one year that would be observed with perfect reporting, screening tests, and screening 
coverage. Under our assumption that each person in the case-rate denominator (N) contributes 
an average of one year of person-time at risk, we calculated the counterfactual incidence of 
correctly diagnosed chlamydia by dividing A by N person-years.  
 
Bias Parameter Inputs: 
 We incorporated sampling distributions for each bias into our calculations to account for 
random error in bias estimates. We conducted literature reviews and sought expert opinion to 
create the sampling distributions. Unless specified otherwise, we created triangular distributions 
to describe the range of plausible bias inputs for each study year. The sampling distributions for 
each bias parameter over the course of the study period are shown in figure 5.  
 
 Reporting Fraction: By 2000, all 50 states and the District of Columbia reported 
chlamydia cases as part of national surveillance (STD disease surveillance). A fraction of cases 
go unreported due to imperfect reporting compliance, but compliance has improved over time 
with the implementation of electronic laboratory reporting systems, which enable cases to be 
reported directly from laboratories. Based on CDC expert opinion, we assumed reporting 
fraction for all age groups increased from approximately 70% to 95% over the study period (40). 
  
 Misclassification Due To Imperfect Screening Tests: We incorporated time-varying 
misclassification due to the use of increasingly sensitive screening tests by considering test use 
and test performance over the study period. Chlamydia screening gradually transitioned from 
 
 22 
low-sensitivity, high-specificity tests, which we refer to as non-nucleic acid amplification tests 
(non-NAATs), to high-sensitivity, high-specificity tests (NAATs). We selected sensitivity and 
specificity values for non-NAATs and NAATs that were consistent with estimates reported in 
previous literature (41–44). We set sensitivity to be 75% and 92% for non-NAATs and NAATs, 
respectively, and specificity to be 99.5% for both test types. We also estimated the proportion of 
screening via non-NAATs and NAATs each year based from regional screening data collected 
as part of the Infertility Prevention Project from 2000 through 2011 (13). We attached lognormal 
distributions to these test use estimates (Figure A3.1). We used these annual test use estimates 
to calculate weighted-average sensitivity and specificity estimates for screening tests each year. 
 
 Screening Coverage: Inputs for screening coverage were based upon coverage reported 
by the Healthcare Effectiveness Data and Information Set (HEDIS), and CDC expert 
opinion(40,45). Annual coverage estimates from HEDIS are derived from women enrolled in 
commercial healthcare plans or Medicaid, and calculated as the women screened for chlamydia 
out of all sexually active women who saw a healthcare provider. HEDIS provides screening 
coverage estimates for women aged 15 through 24, as well as women aged 15 through 20 and 
aged 21 through 24 because screening coverage among younger women is typically lower than 
coverage among older women. For study each year and each age group, we considered the 
screening coverage estimate among women enrolled in commercial insurance plans and 
Medicaid, and calculated the midpoint of these estimates. Based on these midpoints and CDC 
expert opinion, we selected plausible screening coverage estimates for 2000 through 2015. 
Estimates for all women age 15 through 24 increased from 30% in 2000 to 50% in 2015. 
Estimates for women age 20 through 24 increased from 30% to 55%. Estimates for women age 






Sensitivity and Influence Analyses: 
 We conducted several sensitivity analyses for case rate corrections among women aged 
15 through 24 to address potential systematic error in literature reporting estimates screening 
test sensitivity and screening coverage. Screening test sensitivity estimates in literature are 
variable, so we incorporated sensitivity estimates of non-NAATs and NAATs that were 
reasonable lower and upper bounds of our initial inputs. These new sensitivity estimates were 
selected based on approximate upper and lower bounds of sensitivity reported in literature. We 
specified low non-NAAT and NAAT sensitivities of 70% and 85%, and high non-NAAT and 
NAAT sensitivities of 85% and 97% (42,44).  
 
 We also incorporated a range of screening coverage estimates to account for limitations 
of HEDIS coverage estimates. Estimates from HEDIS capture only women who are enrolled in a 
commercial health plan or Medicaid and have an indicator of sexually activity, and may not be 
representative of screening coverage in the underlying population. Therefore, we incorporated 
estimates of screening coverage that we considered to be the plausible lower bound of 
coverage for women age 15 through 24 over the study period, and estimates that we considered 
to be the plausible upper bound of coverage. We selected coverage that increased from 20% to 
40% over time (lower bounds), and coverage that increased from 40% to 60% over time (upper 
bounds).  
 
 Finally, to understand whether one bias or set of biases was particularly influential, we 
examined scenarios in which reported case rates were corrected for only under-reporting, only 
imperfect screening tests, or only coverage. We also examine a scenario in which reported case 






 Limitations for Aim 2 stem from concerns about the validity of estimates used to 
generate bias parameters, and a paucity of data informing some bias parameters. Individual 
estimates of reporting, test sensitivity and specificity, or coverage may be influenced by internal 
biases and may have limited external validity. Incorporating uncertainty into the estimates of 
biases helped mitigate these concerns. 
 
  We did not have enough data to properly account for bias due to case mix. To account 
for case mix, analyses should be completed separately for sub-population with similar 
chlamydia risk factors and therefore similar chlamydia risk. We did not have about data to 




CHAPTER FOUR: SPECIFIC AIM 1 RESULTS 
4.1 INTRODUCTION 
 Chlamydia trachomatis (chlamydia) infection is usually asymptomatic, but can result in 
serious reproductive sequelae if left untreated. In response to the high burden of chlamydia 
among young women, the Centers for Disease Control and Prevention introduced a regional 
federally funded chlamydia screening program in 1988. By 1995, screening programs were 
implemented in all regions of the US as part of the Infertility Prevention Project (13,46). The 
screening programs strengthened clinical, educational, laboratory, and surveillance operations 
related to chlamydia and supported screening and treatment services for low-income, sexually 
active women attending public clinics. The goals were to identify and treat infections, which in 
turn prevents transmission and reduces incidence and prevalence (14). 
 
 At the population level, a reduction in chlamydia prevalence should be observable in 
sentinel populations if national screening programs achieve sufficiently high penetration (26). A 
primary source for sentinel surveillance of chlamydia in the U.S. is the National Job Training 
Program (NJTP), a vocational training program for socioeconomically disadvantaged 
adolescents and young adults administered by the Department of Labor (1,33,34). The NJTP 
has maintained consistent eligibility criteria over time and screens all entrants for chlamydia, 
making it a stable, high-risk population ideal for monitoring chlamydia prevalence. Among NJTP 
enrollees, chlamydia prevalence trends spanning short periods have shown modest decreases 
since the early 1990s, suggesting that national screening programs may have had an effect on 




 Observed prevalence trends from sentinel surveillance should be interpreted cautiously 
because of potential biases. Two of the most important sources of bias that can affect 
prevalence trend estimates are time-varying measurement error from changing screening tests 
and sentinel population risk profiles. Changes in measurement error can bias prevalence trend 
estimates when new screening technologies with different sensitivities and specificities are used 
(14,16). Changes in population risk profiles, which we refer to as “case mix,” can bias 
prevalence trend estimates when the relative proportion of high and low-risk individuals 
screened in a sentinel population fluctuates (14). These biases may mask changes in 
prevalence over time, and trend estimates that do not properly account for changes in 
measurement error and case mix may be misleading. 
 
 We examined chlamydia prevalence trends over 23 years among NJTP enrollees, while 
accounting for potential biases associated with changing screening tests and case mix to 
understand whether national chlamydia screening programs may have contributed to declining 
chlamydia prevalence trends among high-risk youth. 
 
4.2 MATERIALS AND METHODS 
Study Population 
 We analyzed annual cross-sectional chlamydia screening data from NJTP enrollees 
from 1990 through 2012. US residents age 16 through 24 who meet low-income criteria and 
face barriers to employment can enroll in the NJTP. Universal chlamydia screening of NJTP 
entrants began in 1990 for women and 2003 for men. Screening was performed by a national 
contract laboratory that used several tests. From 1990 through 1997, cervical or vaginal swabs 
were tested by Pathfinder Enzyme Immunoassays (EIA) (Sanofi Diagnostics Pasteur, Inc, 
Redmond, Washington). Screening tests used from 1998 through February 2000 are unknown. 
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From March 2000 through December 2006, screening was done with Gen-Probe PACE 2 DNA 
hybridization probe (Gen-Probe Inc., San Diego, California) of swabs from women or urine from 
men, or BD ProbeTec ET strand displacement assay (SDA) (Becton-Dickinson, Sparks, 
Maryland) of urine. After December 2006, screening was done by BD ProbeTec ET of swabs or 
urine. 
 
 Eligible participants for these analyses were non-Hispanic White, Black, Hispanic, or 
American Indian women and men entering the NJTP who had a recorded chlamydia screening 
test result. Enrollees were excluded if their chlamydia test result, race/ethnicity, region of 
residence, or screening test type were unknown.  
 
Screening Test Sensitivity and Specificity 
 Pairs of sensitivity and specificity estimates for each screening test and sample type 
were generated through targeted meta-analyses of existing literature. We searched PubMed 
and Scopus using medical subject heading terms and keywords related to chlamydia screening 
and diagnostic accuracy (Appendix 1). We included studies conducted in North America or 
Europe that reported the diagnostic accuracy of the Pathfinder EIA, Gen-Probe PACE 2, and 
BD ProbeTec ET, and from which counts of true positive, true negative, false positive, and false 
negative tests could be extracted or calculated (47–65). Bivariate generalized linear mixed 
effects models with a logit link were used to generate summary sensitivity and specificity 
estimates and corresponding 95% confidence intervals (CI) (Table 1). 
 
Case mix 
 Chlamydia prevalence and case rates are associated with race/ethnicity and geography, 
with Blacks and the South having the highest burden (1,4,7). To assess potential bias from 
longitudinal changes in the demographics of NJTP enrollees, we examined the racial/ethnic and 
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geographical distributions of enrollees over time. We visualized the distribution of race/ethnicity 
and enrollment by region using stacked bar charts, and observed a uniform distribution over 
time for both factors (Figures A2.1-A2.4). We also examined temporal trends in enrollment by 
these factors using logistic regression, with race/ethnicity or region as the dependent variable, 
and study year (continuous) as the independent variable(s). No meaningful variation in the 
relative proportion of race/ethnicity and region over time was observed, and additional results 




 We modeled chlamydia prevalence trends using an expectation-maximization (EM)-
based maximum-likelihood approach that accounts for measurement error due to imperfect 
screening test sensitivity and specificity (36). This approach uses EM to estimate a maximum-
likelihood regression model when the outcome is measured with uncertainty, and allows the 
sensitivity and specificity of screening tests to vary across observations. Our models accounted 
for sensitivity and specificity estimates generated from our meta-analyses. Chlamydial infection 
(positive or negative) was the dependent variable in all models and study year (continuous) was 
the independent variable. The functional form of year was assessed using Akaike information 
criteria and visual inspection, and included quadratic spline terms with three knots in models for 
women and a quadratic term in models for men. Estimated coefficients from the model output 
were used to calculate the probability (prevalence) of chlamydia across study years. Ninety-five 
percent CIs were obtained by bootstrapping (n=200). We compared trends from the EM 
maximum-likelihood regression model (adjusted trends that account for time-varying 
measurement error) to trends from a logistic regression model (unadjusted trends that do not 
account for time-varying measurement error) to assess the impact of changing screening tests 
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on prevalence trend estimates. We also stratified by race/ethnicity and region to examine 
subgroup differences.  
 
Sensitivity Analyses 
 We conducted sensitivity analyses to account for random and systematic error in the 
estimates of test sensitivity and specificity that were used to model prevalence. To account for 
random error, we modeled prevalence using the upper and lower bounds of the 95% CI around 
our summary sensitivity and specificity estimates. To account for systematic error, we re-
estimated test sensitivity and specificity using more selective inclusion/exclusion criteria for the 
meta-analyses. We excluded studies that used the test of interest in their reference test 
definition (reference test bias) or performed repeat testing. We used these new estimates to 
model adjusted prevalence.  
 
 Analyses were performed in Stata version 14.1 (66).  
 
4.3 RESULTS 
Screening Test Sensitivity and Specificity 
 Sensitivity increased over the study period. The estimated sensitivity of EIA, DNA probe, 
and SDA for women was 73%, 80%, and 87% respectively (Table 4.1). Among men, sensitivity 
of DNA probe and SDA was 72% and 95% respectively. All tests had specificities >98%.  
 
Women: 
 From 1990 through 2012, 439,992 women were screened for chlamydia. Relatively few 
women had an uninterpretable screening test result (n=3,466). Due to administrative changes in 
reporting, race/ethnicity could not be determined for approximately 30% of women in 2001 and 
2002. Because missing race/ethnicity in these years was large and associated only with study 
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year, all women in 2001 and 2002 were excluded (n=21,021). Across other years, relatively few 
women had missing race/ethnicity (n=19,703) or region (n=15,613). Chlamydia screening test 
type was unknown for women enrolled between January 1998 and February 2000 (n=26,730) 
and a small number of women in other study years (n=2,969), and these data were considered 
missing. After excluding women with uninterpretable test results or missing data, 350,490 
women (80% of women screened for chlamydia) were included in analyses. 
 
 Most women were Black (58%) and approximately half lived in the South (45%) (Table 
4.2). Two thirds were age 16 through 19 (69%), and few reported symptoms (3%). 
Approximately 40% of women were tested for chlamydia via EIA, 15% were tested by DNA 
probe, and the remainder was tested via SDA of swabs (14%) or urine (30%).  
 
 Unadjusted chlamydia prevalence was high overall, ranging between 15% and 10%. 
Prevalence declined modestly from 1990 through 2003, before rising slightly through 2009 
(Figure 1). After accounting for measurement error associated with different screening tests, we 
observed a higher burden of chlamydia across all years and a sharper decline in prevalence in 
the first half of the study, relative to unadjusted estimates (Figure 4.1). Prevalence was highest 
in 1990 at approximately 20%, and steadily decreased to 12% by 2003. Between 2004 and 
2012, prevalence was relatively steady and rose slightly to 14% before dropping to 12%. 
 
 Black women had the highest burden of chlamydia throughout the study, followed by 
American Indian, Hispanic, and White women (Figure 4.2). For all race/ethnicities, prevalence 
declined early on, with the sharpest decline occurring among American Indian women (24% to 
12%) and Black women (23% to 14%). Among Hispanic and White women, prevalence declined 
from approximately 15% to 10% and 13% to 7% respectively. Adjusting for time-varying 
measurement error revealed a larger decline in prevalence for all race/ethnicities early in the 
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study, relative to unadjusted trends (Figure A2.5). In the second half of the study, chlamydia 
prevalence remained relatively steady among White and Hispanic women. Prevalence in Black 
women rose modestly from 14% to 17% between 2003 and 2008, before beginning to drop. 
American Indian women experienced a slight uptick in prevalence from 2008 through 2012 
(12% to 16%). 
 
 Chlamydia prevalence was highest throughout the study in the South, followed by the 
Midwest, Northeast, and West. In all regions, prevalence was high in 1990, ranging between 
16% in the West to 21% in the South (Figures 4.3 and A2.6). Prevalence declined in the first 
half of the study in all regions, and leveled out in the second half in the West and Northeast. 
Modest increases in prevalence occurred in the South and Midwest between 2004 and 2009.  
 
 In sensitivity analyses, neither the magnitude nor shape of the overall prevalence trend 
was substantially altered by using the lower and upper bounds of the 95% CI around test 
sensitivity and specificity estimates (Figure A2.7). Modeling trends with re-estimated test 
sensitivity and specificity also had minimal influence on the overall trend (results not shown). 
 
Men: 
 From 2003 through 2012, 370,047 men were screened for chlamydia. Few men had an 
uninterpretable test result (n=1,288), or were missing race/ethnicity (n=21,976). Region and 
chlamydia screening test type were missing for 7,486 men and 35,598 men respectively. 
Overall, 303,699 men (82% of men screened for chlamydia) were included in analyses. 
 
 Half of men were Black (51%) and lived in the South (49%) (Table 4.2). Two thirds were 
age 16 through 19 (67%). Few men reported sexually transmitted infection symptoms (1%). 
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Almost all men were screened with SDA (99%). Unadjusted chlamydia prevalence remained 
stable throughout the study, and fluctuated between 8% and 9% (Figure 4.1). 
 
 After accounting for measurement error, the prevalence of chlamydia among men 
decreased slightly in all years relative to unadjusted estimates but remained steady over time at 
approximately 7% (Figure 1). Black men had the highest prevalence across all years 
(approximately 11%), followed by American Indian (approximately 5%), Hispanic (approximately 
4%), and White men (approximately 1%) (Figures 4.2 and A2.8). Prevalence was consistently 
highest in the South, followed by the Midwest, Northeast, and West (Figure 4.3 and A2.9). 
Prevalence estimates generated from the upper and lower bounds of the 95% CI around test 
sensitivity and specificity did not substantially alter trends (Figure A2.10). 
 
4.4 DISCUSSION 
 Chlamydia remains one of the most commonly reported sexually transmitted infections in 
the US despite long-standing national screening and treatment programs (1). Sentinel 
surveillance of chlamydia among NJTP enrollees provides a unique opportunity to evaluate the 
impact of national chlamydia screening programs on prevalence among high-risk youth. After 
ruling out bias due to case mix and adjusting for time-varying measurement error associated 
with changing screening tests, chlamydia prevalence among women declined from 20% to 12% 
during the first 14 years of the study, and hovered between 12% and 14% through 2012. 
Adjusted chlamydia prevalence among men was stable from 2003 through 2012 (approximately 
7%). For women and men, prevalence was highest among Black and American Indian youth, 
and the South and Midwest throughout the study. 
 
 The decline in chlamydia prevalence among women entering the NJTP during the 1990s 
provides support for the early success of screening programs in reducing chlamydia burden. 
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Women in the NJTP are a surrogate for high-risk young women in the general population, and 
falling trends within the NJTP suggest that national screening programs initially may have led to 
a reduction in chlamydia among high-risk young women. After 2003, prevalence stopped 
declining, suggesting that on-going screening efforts targeting high-risk young women were 
ineffective at continuing to reduce prevalence. Current screening efforts may be sufficient to 
stabilize chlamydia prevalence in high-risk populations, but are unlikely to drive any further 
decline.  
 
 Chlamydia prevalence among men was steady throughout the study. Screening for men 
started in 2003, when the prevalence among women began to stabilize. Prevalence among men 
may have declined similarly to women prior to 2003 since men are a reservoir for chlamydia. 
The flat trend signals that ongoing prevention efforts have been ineffective at reducing 
chlamydia among men. 
 
 We observed large disparities in chlamydia prevalence by race/ethnicity and region, with 
Blacks, American Indians, and the South having consistently higher prevalence compared to 
other races/ethnicities and regions. Prevalence in these groups also increased modestly during 
the latter half of the study. Similar racial and regional disparities have been observed among 
large population-based surveys and public high school students (4,5,7,67,68). The NJTP 
population consists of socioeconomically disadvantaged youth and our results cannot be 
generalized to all youth. However, consideration of targeted chlamydia prevention efforts for 
these groups is warranted since racial and regional disparities exist in multiple populations. 
 
 Our findings differ from previously reported chlamydia prevalence trends among NJTP 
enrollees with respect to trend direction, duration, and validity. Previously reported trends are 
decreasing but estimated only over the short-term. (19–22) While focusing on shorter periods 
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may avoid bias from changing tests, it prohibits trend comparisons across periods with different 
tests. Additionally, time spans may be too short to observe the impact of screening on a 
population level. We examined 23-year prevalence trends to generate a comprehensive picture 
of chlamydia burden over time, and observed no substantial decline after 2003. 
 
 We also used robust methods to account for measurement error due to changing 
screening tests. In previous trend estimates, measurement error was addressed by controlling 
for screening tests in generalized linear models or restricting by test type (20,21). These 
methods do not account for differing test sensitivities and specificities (15). To generate more 
valid prevalence estimates that correctly account for measurement error, we estimated 
screening tests’ diagnostic accuracy through meta-analyses, and used EM-based maximum-
likelihood regression to incorporate sensitivities and specificities into prevalence trend 
estimation. We examined several sensitivity and specificity estimates to account for random and 
systematic error that may have influenced our diagnostic accuracy estimates. Sensitivity 
analyses showed that adjusted prevalence trend estimates were generally unaffected by a 
range of plausible screening test sensitivity and specificity values. 
 
 Additionally, we evaluated the need to account for case mix by examining characteristics 
of NJTP enrollees over time. NJTP entrance criteria for socioeconomic status, education, and 
age were constant throughout the study (34), and we did not observe meaningful variation in 
race/ethnicity or region over time. We could not assess whether characteristics of individuals 
meeting NJTP entrance criteria changed over time, so although entrance criteria were 
consistent, risk profiles of enrollees, such as sexual behavior, could have changed. Still, 
unchanged criteria helped ensure that the relative proportion of major risk factors for chlamydial 




 We acknowledge that factors other than screening program effectiveness or biases in 
surveillance data could have influenced chlamydia prevalence trends. Two such factors are 
changes in sexual behaviors and increased condom use. These factors drove falling teen 
pregnancy trends (69), which declined similarly to chlamydia in the 1990s but continued to drop 
steadily through 2012 while chlamydia trends plateaued or rose, suggesting that multiple factors 
played a role in the early decline of chlamydia. We cannot evaluate whether additional factors 
influenced chlamydia trends for this study. However, in the absence of more complete data 
about the impact of screening programs or potential influential factors, sentinel surveillance data 
are uniquely informative for chlamydia screening program effectiveness. Our study addresses 
two of the most important biases that can impact prevalence (measurement error and case mix) 
and was not subject to biases from changes in healthcare seeking behaviors, coverage, or 
reporting. Thus, we believe that chlamydia screening programs contributed to the decline in 
chlamydia prevalence in the 1990s. 
 
 Our study is the first to generate long-term chlamydia prevalence trend estimates among 
NJTP enrollees while properly accounting for biases that influence observed prevalence in 
sentinel populations. We observed an initial decline in chlamydia prevalence among women, 
followed by a period of stagnation. The trend is evidence that chlamydia screening programs 
were initially effective on a population level, but screening later lost momentum in reducing 
chlamydia prevalence, which remained high despite the initial decline. Although screening 
programs may have impacted related outcomes, such as reproductive sequelae or HIV 
transmission, evaluating programs’ success by monitoring the incidence of related outcomes is 
difficult since these outcomes have multiple etiologies. Therefore, monitoring chlamydia 
prevalence is an important part of chlamydia control. Chlamydia prevalence among high-risk 





4.5 TABLES AND FIGURES 
Table 4.1: Summary sensitivity and specificity estimates of chlamydia screening tests 
Screening Test (sample type)   
No. of 
Studies(Ref)    Sensitivity (95% CI)   Specificity (95% CI) 
Women 
	 	 	 	 	 	 	 	Pathfinder EIA (Swab)1 
	
   2(47,48) 
	
72.92 (39.07, 91.88) 
	
99.64 (98.14, 99.93) 
Gen-Probe PACE 2 DNA Probe (Swab)2 
	
  11(47,49–58) 
	
80.07 (76.66, 83.08) 
	
99.21 (98.43, 99.60) 
BD ProbeTec ET SDA (Urine)3     4(60,62–64)  87.82 (83.74, 90.99)  99.10 (97.66, 99.66) 
BD ProbeTec ET SDA (Swab)4 
	
   6(59–64) 
	
87.49 (81.27, 91.86) 
	
99.47 (98.69, 99.79) 
Men 
	 	 	 	 	 	 	 	Gen-Probe PACE 2 DNA Probe (Urine)2 
	
   3(51,55,65) 
	
72.09 (60.07, 81.61) 
	
99.17 (97.04, 99.77) 
BD ProbeTec ET SDA (Urine)3      3(60,62,63)   94.04 (91.54, 95.83)   98.21 (91.32, 99.65) 
1Used for screening from 1990 through 1997 
2Used for screening from March 2000 through 2006 for women, and 2003 through 2006 for men 
3Used for screening from 2000 through 2012 for women, and 2003 through 2012 for men 





























	 	 	 	 	
 
	16-19 242,330 (69.1) 32,631  13.5   204,778 (67.4) 16,147  7.9  








Black 202,707 (57.8) 29,445  14.5    
	
155,045 (51.1) 19,031  12.3  
White 82,366 (23.5) 6,116  7.4   
	
95,994 (31.6)  2,761  2.9  
Hispanic 54,799 (15.6) 5,527  10.1   
	
44,822 (14.8)  2,713  6.1  
American Indian 10,618  (3.0) 1,286  12.1   
	










Midwest 64,153 (18.3) 7,911  12.3   
	
51,361 (16.9)  4,423  8.6  
Northeast 60,654 (17.3) 6,321  10.4   
	
45,730 (15.1)  2,893  6.3  
South 157,294 (44.9) 22,047  14.0   
	
149,464 (49.2) 14,983  10.0  
West 68,389 (19.5) 6,095  8.9   
	
57,144 (18.8)  2,415  4.2  









Yes 10,365  (3.0) 1,556  15.0   
	
3,707  (1.2)    673  18.2  
No 340,125 (97.0) 40,818  12.0   
	
299,992 (98.8) 24,041  8.0  









EIA (swab) 141,932 (40.5) 17,811  12.5   
	
-- -- --  --  
DNA Probe 
(swab) 53,812 (15.4) 5,139  9.5   
	
-- -- --  --  
DNA Probe (urine) -- -- --  --  
	
954  (0.3)    83  8.7  
SDA (swab) 47,690 (13.6) 6,779  14.2   
	
    --   -- --  --  
SDA (urine) 107,056 (30.5) 12,645  11.8   
	






              









No. Tested (Col %) No. Positive 
Unadjusted 
Prevalence (%)2 
Year of Test              
1990 10,143  (2.9) 1,518  15.0    -- -- --  --  
1991 18,086  (5.2) 2,588  14.3    -- -- --  --  
1992 18,922  (5.4) 2,380  12.6    -- -- --  --  
1993 20,132  (5.7) 2,484  12.3    -- -- --  --  
1994 19,994  (5.7) 2,722  13.6    -- -- --  --  
1995 18,151  (5.2) 2,276  12.5    -- -- --  --  
1996 21,115  (6.0) 2,235  10.6    -- -- --  --  
1997 15,389  (4.4) 1,608  10.4    -- -- --  --  
2000 8,274  (2.4) 938  11.3    -- -- --  --  
2003 16,095  (4.6) 1,598  9.9    16,206  (5.3) 1,447  8.9  
2004 17,936  (5.1) 1,862  10.4    32,593 (10.7) 2,766  8.5  
2005 19,114  (5.5) 1,758  9.2    33,637 (11.1) 2,849  8.5  
2006 19,339  (5.5) 2,611  13.5    32,652 (10.8) 2,699  8.3  
2007 20,825  (5.9) 2,811  13.5    33,147 (10.9) 2,683  8.1  
2008 21,494  (6.1) 2,743  12.8    33,158 (10.9) 2,624  7.9  
2009 21,288  (6.1) 2,518  11.8    31,435 (10.4) 2,411  7.7  
2010 21,948  (6.3) 2,669  12.2    30,421 (10.0) 2,346  7.7  
2011 22,162  (6.3) 2,646  11.9    31,661 (10.4) 2,581  8.2  
2012 20,083  (5.7) 2,409  12.0    28,789  (9.5) 2,308  8.0  
1Data from 1998-March 2000 were excluded due to missing chlamydia screening test type. Data from 2001-2002 were excluded due to missing 
race/ethnicity. 
2Unadjusted prevalence was calculated as the total number of positive tests divided by the total number tested. Estimates differ slightly from 
estimates derived from logistic regression models.  
3Unadjusted prevalence estimates among women in years excluded from analyses are as follows: 1998: 11.8%; 1999: 11.5%; 2000 (all months): 





Figure 4.1: Adjusted and unadjusted chlamydia prevalence among women and men entering 
the NJTP, 1990-2012  
 
 
 Adjusted and unadjusted chlamydia prevalence among women entering the NJTP 
(n=350,490) from 1990-2012 and men entering the NJTP (n= 303,699) from 2003-2012. 
Adjusted prevalence estimates and 95% CIs account for measurement error associated with 
use of increasingly sensitive chlamydia screening tests over time (Pathfinder EIA of swabs 
[1990-1997], Gen-Probe PACE 2 DNA hybridization probe of urine or swabs [2000-2006], and 
BD ProbeTec ET SDA of urine [2000-2012] or swabs [2007-2012]). Adjusted estimates were 
modeled using an EM algorithm incorporated into logistic regression. Unadjusted estimates 
were generated from a logistic regression model, and do not account for changes in the 
diagnostic accuracy of tests. Note: Women enrolled in January 1998-February 2000 and 2001-




Figure 4.2: Adjusted chlamydia prevalence and 95% CIs among women and men entering the 
NTJP by race/ethnicity, 1990-2012. 
 
 Adjusted chlamydia prevalence and 95% CIs among Hispanic (n=54,799), Black 
(n=202,707), White (n=82,366), and American Indian (n=10,618) women entering the NJTP, 
1990-2012 (Panel A) and Hispanic (n=44,822), Black (n=155,045), White (n=95,994), and 
American Indian (n=7,838) men entering the NJTP, 2003-2012 (Panel B). Adjusted prevalence 
was modelled using an EM algorithm incorporated into logistic regression to account for 
measurement error due to changes in the diagnostic accuracy of chlamydia screening tests over 




Figure 4.3: Adjusted chlamydia prevalence and 95% CIs among women and men entering the 




 Adjusted chlamydia prevalence and 95% CIs among women entering the NJTP in four 
regions of the US, 1990-2012 (Midwest: n=64,153; South: n=157,294; West: n=68,389; 
Northeast: n=60,654) (Panel A) and men entering the NJTP in four regions of the US, 2003-
2012 (Midwest: n=51,361; South: n=149,464; West: n=57,144; Northeast: n=45,730) (Panel B). 
Adjusted prevalence was modelled using an EM algorithm incorporated into logistic regression 
 
 42 








 Chlamydia is the most commonly reported sexually transmitted disease (STD) in the US 
(1). Because infections are often asymptomatic, routine screening of young, sexually active 
women to detect and treat disease is important for preventing reproductive sequelae and 
reducing chlamydia incidence (1–7). Nationally notifiable STD surveillance data collected by the 
Centers for Disease Control and Prevention (CDC) show annual chlamydia case rates among 
young women aged 15 through 24 years climbed from 2000 through 2011, and then shifted to a 
downward trend through 2014(1). At first glance, the downward shift may suggest chlamydia 
incidence is decreasing; however, interpreting trends in reported chlamydia case rates is 
challenging.  
 
 Case rates, which are calculated by dividing the number of reported chlamydia cases in 
a given year by the size of the at-risk population (estimated using census data), may be 
influenced not only by changes in true incidence of infection, but also by several time-varying 
biases, such as changes in screening coverage, diagnostic technologies, and reporting 
practices. The observed increase in chlamydia case rates during 2000 through 2011 may be a 
result of expanded screening coverage, the use of increasingly sensitive diagnostic tests, and 
improvements in reporting practices over that period. (1,8–11) In the current era of widespread 
use of highly sensitive tests and electronic reporting systems which ensure most positive tests 
are reported to local health authorities, falling case rates may reflect a true decline in incidence 
or changes in screening coverage. The time-varying roles of each of these forces must be 
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carefully considered in interpreting case rate trends, but to date no study has quantified biases 
and examined their joint influence on reported case rates trends.  
 
 The goal of this study was to account for these time-varying biases in calculating the 
annual incidence of diagnosed and reported chlamydia that would have been observed with 
perfect screening coverage, diagnostic tests, and case reporting among young women in the 
US from 2000 through 2015. 
 
5.2 MATERIALS AND METHODS 
 Our estimation approach was based on a conceptual diagram of relationship between 
the at-risk population and surveillance-related biases (Figure 5.1). We start with a dynamic 
population of at-risk women in steady-state. Within this population are all chlamydial infections 
(“true cases”), as well as the proportion of this population is screened for chlamydia. Some 
proportion of the population is diagnosed with chlamydia, and some proportion of women 
diagnosed with chlamydia is reported as chlamydia cases (“reported cases”). Reported 
chlamydia cases are an underestimate of true chlamydia cases in the population as a result of 
partial screening coverage (i.e., not all at-risk women are screened), misclassification due to 
imperfect diagnostic tests (i.e., diagnostic tests are <100% sensitive), and under-reporting (i.e., 
some diagnosed infections are not reported).  
 
 We implemented a series of corrections that addressed each bias successively, and 
calculated an annual counterfactual incidence rate of correctly diagnosed chlamydia that would 
be observed with perfect screening coverage, diagnostic tests, and reporting. This 
counterfactual incidence rate of diagnosis represents the case rate that we would expect if 
every at-risk individual were screened once annually using perfect diagnostic tests, and if every 
chlamydia diagnosis was reported. To calculate the counterfactual incidence rate of correctly 
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diagnosed chlamydia we corrected annual case rates for under-reporting, case misclassification 
due to imperfect diagnostic tests, and partial screening coverage, respectively. We corrected 
reported case rates among all women aged 15 through 24 years, and stratified case rates by 
age group (15 through 19 years, and 20 through 24 years) to examine variation in trends among 
younger and older women. Our approach allowed for temporal variation in biases to reflect 
improvements over time in screening coverage, use of more sensitive diagnostic tests, and 
reporting completeness. 
 
Case Rate Inputs 
 Reported chlamydia case rates for women in our target age groups (ages 15 through 24 
years, 15 through 19 years, and 20 through 24 years) in the US from 2000 through 2015 were 
obtained from the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
AtlasPlus tool. (12) Case rate numerators represent the total number of chlamydia cases 
(diagnoses) reported to the CDC in one year by state and local health authorities in all 50 states 
and the District of Columbia. Case rate denominators are calculated as the US census 
population of women of the target ages in a given year.  
 
Corrections for Biases: 
 We made a series of simple corrections to annual reported chlamydia case rates to 
account for under-reporting, imperfect diagnostic tests, and partial screening coverage.  
For a given year, we defined the following: 
C = number of reported cases (case rate numerator) 
N = total at-risk population (case rate denominator) 
R = proportion of chlamydia diagnoses that were reported to CDC through national 




Se= diagnostic test sensitivity 
Sp = diagnostic test specificity 
Sc = proportion of the at-risk population screened for chlamydia (screening coverage) 
 
 In each study year, we took 200 random draws from distributions describing reporting, 
diagnostic tests, and screening coverage (see “Bias Parameter Inputs” below) to define values 
for the inputs R, Se, Sp, and Sc above. With the values in each draw, we performed the 
calculations described below to estimate the counterfactual incidence of correctly diagnosed 
chlamydia in a given year. We then compared the annual medians of these corrected rates to 
the reported chlamydia case rates from 2000 through 2015 to assess the impact of these biases 
on reported trends. 
 
Correcting for under-reporting 
 To correct for under-reporting of chlamydia cases, we divided reported chlamydia cases 
[C] by the reporting fraction [R]. This step generated the counterfactual count of chlamydia 
diagnoses (both true and false positives) among women screened that we would expect to be 
included in case rate estimates under perfect reporting. 
 
Correcting for misclassification due to imperfect diagnostic tests 
 To calculate the number of true chlamydia cases among women who were screened in a 
given year, which we will call A, we corrected for misclassification of chlamydia cases due to 
imperfect diagnostic test sensitivity and specificity following Greenland,1996 (38),  
  








where FrT is the number of false positive diagnoses per unit person-time among women 
screened. If we assume that each individual in a given annual case rate denominator (N) 
contributes, on average, one year of person time during which he or she is at risk of chlamydia 
diagnosis that year, FrT can be calculated as  
 
    !"# = 1 − !" ∗ 1 − ! ∗ !"#, 
 
where P is the underlying true prevalence of chlamydia in the screened population. This 
assumption is valid if 1) the at-risk population is dynamic and in steady-state (39), 2) person-
time contributed by unidentified true cases is relatively small, and 3) identified cases are treated 
and promptly return to the pool of at-risk women.  
 
 We derived annual prevalence as follows: In a steady-state population with non-
differential screening according to true chlamydial infection, the cumulative number of 
diagnosed cases among women screened [C/R] in a given year should equal the number of 
new diagnoses that would be observed in a one-time screening process conducted in the 
population that year. This number, in turn, is equal to the total number of true and false positives 
that would be observed in that screening process, which can be calculated as !"#(!"# +







Substituting this expression for prevalence into Equation 2 above allowed us to calculate FrT, 





chlamydia cases that would have been observed among women screened under perfect 
reporting and diagnostic test performance [A].  
 
Correcting for partial screening coverage 
 To correct for screening coverage, we divided the number of diagnoses of true 
chlamydia cases among women screened [A] by the screening coverage [Sc]. This step gave us 
the counterfactual number of correctly diagnosed chlamydia cases in the total at-risk population 
over one year that would be observed with perfect reporting, diagnostic tests, and screening 
coverage. Under our assumption that each person in the case-rate denominator (N) contributes 
an average of one year of person-time at risk, we calculated the counterfactual incidence of 
correctly diagnosed chlamydia by dividing A by N person-years.  
 
Bias Parameter Inputs: 
 We incorporated sampling distributions for each bias into our calculations to account for 
random error in bias estimates. We conducted literature reviews and sought expert opinion to 
create the sampling distributions. Unless specified otherwise, we created triangular distributions 
to describe the range of plausible bias inputs for each study year, and describe the modes of 
distributions below. Sampling distributions for each bias parameter over the course of the study 
period are shown in Figure 5.2.  
 
 Reporting Fraction: By 2000, all 50 states and the District of Columbia reported 
chlamydia cases as part of national surveillance (STD disease surveillance). A fraction of cases 
go unreported due to imperfect reporting compliance, but compliance has improved over time 
with the implementation of electronic laboratory reporting systems, which enable cases to be 
reported directly from laboratories. Based on CDC expert opinion, we assumed reporting 




 Misclassification Due To Imperfect Diagnostic Tests: We incorporated time-varying 
misclassification due to the use of increasingly sensitive diagnostic tests by considering test use 
and test performance over the study period. Chlamydia screening gradually transitioned from 
low-sensitivity, high-specificity tests, which we refer to as non-nucleic acid amplification tests 
(non-NAATs), to high-sensitivity, high-specificity tests (NAATs). We selected sensitivity and 
specificity values for non-NAATs and NAATs that were consistent with estimates reported in 
previous literature. (41–44) We set sensitivity to be 75% and 92% for non-NAATs and NAATs, 
respectively, and specificity to be 99.5% for both test types. We also estimated the proportion of 
screening via non-NAATs and NAATs each year based from regional screening data collected 
as part of the Infertility Prevention Project from 2000 through 2011. (13) We attached lognormal 
distributions to these test use estimates (Figure A3.1). We used these annual test use estimates 
to calculate weighted-average sensitivity and specificity estimates for diagnostic tests each 
year. 
 
 Screening Coverage: Inputs for screening coverage were based upon coverage reported 
by the Healthcare Effectiveness Data and Information Set (HEDIS), and CDC expert opinion. 
(40,45) Annual coverage estimates from HEDIS are derived from women enrolled in commercial 
healthcare plans or Medicaid, and calculated as the women screened for chlamydia out of all 
sexually active women who saw a healthcare provider. HEDIS provides screening coverage 
estimates for women aged 15 through 24 years, as well as women aged 15 through 20 years 
and aged 21 through 24 years because screening coverage among younger women is typically 
lower than coverage among older women. For study each year and each age group, we 
considered the screening coverage estimate among women enrolled in commercial insurance 
plans and Medicaid, and calculated the midpoint of these estimates. Based on these midpoints 
and CDC expert opinion, we selected plausible screening coverage estimates for 2000 through 
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2015. Estimates for all women aged 15 through 24 years increased from 30% in 2000 to 50% in 
2015. Estimates for women age 20 through 24 years increased from 30% to 55%. Estimates for 
women aged 15 through 19 years increased from 30% to 45%. 
 
Sensitivity and Influence Analyses: 
 We conducted several sensitivity analyses for case rate corrections among women aged 
15 through 24 years to address potential systematic error in literature reporting estimates 
diagnostic test sensitivity and screening coverage. Diagnostic test sensitivity estimates in 
literature are variable, so we incorporated sensitivity estimates of non-NAATs and NAATs that 
were reasonable lower and upper bounds of sensitivity estimates. These new sensitivity 
estimates were selected based on approximate upper and lower bounds of sensitivity reported 
in literature. We specified low non-NAAT and NAAT sensitivities of 70% and 85%, and high non-
NAAT and NAAT sensitivities of 85% and 97%. (42,44)  
 
 We also incorporated a range of screening coverage estimates to account for limitations 
of HEDIS coverage estimates. Estimates from HEDIS capture only women who are enrolled in a 
commercial health plan or Medicaid and have an indicator of sexually activity, and may not be 
representative of screening coverage in the underlying population. Therefore, we incorporated 
estimates of screening coverage that we considered to be the plausible lower bound of 
coverage for women aged 15 through 24 years over the study period, and estimates that we 
considered to be the plausible upper bound of coverage. We selected coverage that increased 
from 20% to 40% over time (lower bounds), and coverage that increased from 40% to 60% over 
time (upper bounds).  
 
 Finally, to understand whether one bias or set of biases was particularly influential, we 
examined scenarios in which reported case rates were corrected for only reporting fraction, only 
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imperfect diagnostic tests, or only coverage. We also examined a scenario in which reported 
case rates were corrected for reporting fraction and imperfect diagnostic tests.  
 
5.3 RESULTS: 
 Reported chlamydia case rates among women 15 through 24 years generally increased 
over the study period. Case rates rose from approximately 2,200 cases per 100,000 person-
years in 2000 to 3,600 cases per 100,000 person-years in 2011. Between 2011 and 2014, case 
rates modestly declined from 3,300 cases per 100,000 person-years before increasing to 3,400 
cases per 100,000 person-years in 2015 (figure 5.3A).  
 
 After correcting reported case rates among women aged 15 through 24 years for time-
varying reporting fraction, diagnostic tests, and screening coverage, counterfactual incidence 
rates of correctly diagnosed chlamydia, which we will refer to as incidence rates, were higher 
than reported case rates, but incidence rate trends declined substantially over time (figure 
5.3A). Incidence rates of correctly diagnosed chlamydia fell sharply between 2000 and 2007 
(approximately 12,900 cases per 100,000 person-years to 7,900 cases per 100,000 person-
years). Between 2008 and 2015, incidence rates were fairly steady, but rose modestly to 8,000 
cases per 100,000 person-years in 2008 before dropping to 7,100 cases per 100,000 person-
years in 2015.  
 
 Stratifying by age group showed that reported case rates among younger women and 
older women also rose from 2000 through 2011 (figure 5.3B). Reported case rates among 
women in both age groups were nearly identical from 2000 through 2011, and case rates 
increased from approximately 2,100 cases per 100,000 person-years to 3,500 cases per 
100,000 person-years. After 2011, case rates among older women continued rising to 3,700 
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cases per 100,000 person-years by 2015, while case rates among younger women dropped to 
3,000 cases per 100,000 person-years by 2015.  
 
 Incidence rate trends of correctly diagnosed chlamydia among younger and older 
women declined, but the shape of the trends differed between the two age groups (figure 5.3B). 
Younger women experienced a more dramatic decline in incidence rates trends compared to 
older women. In 2000, incidence rates among younger women were higher than incidence rates 
among older women (13,700 cases per 100,000 person-years versus 12,100 cases per 100,000 
person-years, respectively). Incidence rates for both age groups were equal by 2015 (7,000 
cases per 100,000 person-years). In addition, incidence rates among older women held steady 
at approximately 7,000 cases per 100,000 person-years from 2009 through 2015, while 
incidence rates among younger women during the same time period dropped from 9,600 cases 
per 100,000 person-years to 7,000 cases per 100,000 person-years. 
 
 In sensitivity analyses, we examined different estimates of diagnostic test sensitivity and 
screening coverage. Scenarios with the lower bound of coverage estimates produced sharper 
declines in incidence rates compared to scenarios with the upper bound of coverage estimates 
(figure 5.4). Incorporating upper and lower bounds of plausible diagnostic test sensitivities 
influenced the magnitude but not shape of incidence rate trends, with lower sensitivities 
resulting in higher incidence rates and vice versa.  
 
 In our influence analysis, the impact of correcting for reporting and imperfect diagnostic 
tests individually (figure 5.5A) or jointly (figure 5.5B) was small. Incidence rates corrected for 
these biases were only slightly larger than reported case rates, and trends followed roughly the 
same shape as report case rate trends. Correcting for screening coverage has a noticeable 
impact. Compared to reported case rates, incidence rates corrected for only for screening 
 
 53 
coverage were higher, and trends were relatively stable (approximately 7,900 cases per 
100,000 person-years).  
 
5.4 DISCUSSION 
 We estimated counterfactual incidence rates of correctly diagnosed chlamydia among 
young women that would be obtained in the absence of bias from partial screening coverage, 
imperfect diagnostic tests and under-reporting. Counterfactual incidence rates represent the 
chlamydia case rate that would be observed if the total at-risk population was screened once 
per year using perfect diagnostic tests, and if all cases were reported. After correcting 
chlamydia case rates for time-varying biases, we observed that counterfactual incidence rate 
trends among women aged 15 through 24 years declined over the study period. Trends 
declined sharply in the first half of the study period and modestly in the second half of the study 
period. When stratified by age, incidence rate trends among women aged 15 through 19 years 
and 20 through 24 years also declined, but incidence rates among younger women were higher 
and generally declined for most of the study period, while incidence rates among older women 
were fairly steady after 2009. 
 
 Our results suggest that the increase in reported chlamydia case rates among young 
women may be due to time-varying biases. Chlamydia screening programs have been in place 
since the early 1990s, and should lead to a decrease in incidence, as screening and treatment 
shorten disease duration and help prevent ongoing transmission.(20) Biases in surveillance 
data may mask declining incidence trends that are expected to occur with widespread 
screening. By correcting case rates for time-varying biases, we attempted to disentangle the 
influence of biases on incidence rate trends. The downward trend in counterfactual incidence 
rates of correctly diagnosed chlamydia suggests that, in the absence of bias related to 
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screening coverage, diagnostic tests and reporting, chlamydia incidence rates among young 
women may be substantially higher than reported case rates but may be declining over time.  
 
 We also observed differences in the counterfactual incidence rates trends of correctly 
diagnosed chlamydia among women aged 15 through 19 years and women aged 20 through 24 
years. Trends among younger women generally declined throughout the study period, while 
trends among older women leveled off in the later half of the study period. The difference in 
trends may be due to differences in sexual risk behaviors and healthcare access among 
younger and older women over time. Determining if changes in behavior or healthcare access 
are contributing to trends among younger and older women is an important area for future 
research.  
 
 Declining counterfactual incidence rates of correctly diagnosed chlamydia are 
suggestive of a decrease in chlamydia burden over time, but incidence rates of diagnosis differ 
from incidence rates of infection. Chlamydia case rates are flawed measures of incidence rates 
of diagnosis, and we estimated counterfactual incidence rates of diagnosis to understand what 
surveillance systems would capture if screening coverage, diagnostic tests, and reporting were 
perfect. From a public health perspective, incidence of infection may be a more informative 
measure of chlamydia burden. The incidence of infection may be higher or lower than the 
incidence of diagnosis in a given year depending on infection duration and when screening 
occurs. Surveillance systems cannot capture the incidence of infection and instead provide an 
estimate of the incidence of diagnosis, but with increasing screening coverage and test 
sensitivity, and declining steady-state chlamydia prevalence, we would expect incidence rates of 




 In influence analyses, bias from screening coverage, more so than bias from reporting 
and diagnostic tests, had a substantial impact on the shape of counterfactual incidence rate 
trends. Counterfactual incidence rate trends were predominately driven by changes in coverage. 
Our results suggest that understanding the relationship between coverage and incidence rates 
is critical for interpreting incidence rate trends, and highlight the need for accurate estimates of 
coverage. Existing estimates have significant limitations. Estimates from HEDIS or other claims 
data are derived from women presenting to care who are sexually active and receive screening. 
These estimates may over-estimate coverage and lack generalizability because they fail to 
capture women who seek care at out-of-plan facilities. They are also affected by healthcare 
access. (22–29) Estimates are also derived from the self-report data collected by the National 
Survey for Family Growth (NSFG). NSFG may more accurately capture sexual activity among 
women and therefore be a better indicator of who should be screened, but may less accurately 
capture actual screening due to recall bias or social desirability bias. (30) Further, estimates 
from claims data and self-report data generally have poor concordance. (30,31) More valid 
estimates of coverage are important for understanding whether screening targets are met, and 
for a more valid interpretation of chlamydia case rate trends derived from surveillance data. 
 
 Our study demonstrates how biases present in surveillance data limit interpretability of 
reported chlamydia case rate trends. After correcting for time-varying reporting, diagnostic tests, 
and screening coverage, we observed that counterfactual incidence rates of correctly diagnosed 
chlamydia among young women were higher than reported case rates and decreased over the 
study period. Our results suggest that reported case rates from 2000 through 2011 may have 
increased due to the influence of time-varying biases, and that the incidence of diagnosis of 





Figure 5.1: Conceptual diagram depicting surveillance data biases in relation to the at-risk 






 True chlamydia cases exist within a dynamic, steady state population of at-risk young 
women. A proportion of chlamydia cases and non-cases are screened, classified as cases, and 
reported as cases. The three inner ellipses represent bias due partial screening coverage, 
imperfect diagnostic tests, and under-reporting. The extent to which biases influence reported 
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Figure 5.2: Inputs of reporting fraction, diagnostic test sensitivity and specificity, and screening 




 Solid lines represent the mode of triangular distributions and shaded areas cover the 
range between the lower and upper limits of distributions. Coverage estimates for age-stratified 
analyses are not depicted, but were as follows: for women aged 15 through 19 years, coverage 
increased from 30% to 45% (increasing one percentage point per year from 2000 through 
2015). For women aged 20 through 24 years, coverage increased from 30% to 55% (increasing 
two percentage points per year from 2000 through 2010 and one percentage point per year from 
2011 through 2015). Note: Test sensitivity was a weighted-average of non-NAAT and NAAT 
sensitivity based on annual test use (figure A3.1). The shaded area above is the approximate 





Figure 5.3: Reported chlamydia case rates and counterfactual incidence rates of correctly 








 Reported chlamydia case rates and counterfactual incidence rates of correctly 
diagnosed chlamydia from 2000 through 2015 among young women aged 15 through 24 (panel 
A) and among women stratified into two age groups (panel B). Counterfactual incidence rates 
were generated by correcting reported case rates for time-varying reporting fraction, diagnostic 




Figure 5.4: Sensitivity analyses of counterfactual incidence rates of correctly diagnosed 





 The upper bound of screening coverage ranged from 40% to 60% over the study period 
and lower bound ranged from 20% to 40% over the study period. Low non-NAAT and NAAT 
sensitivity was 70% and 85%, respectively. High non-NAAT and NAAT sensitivity was 85% and 







Figure 5.5: Influence analyses of counterfactual incidence rates of correctly diagnosed 








 Influence analyses of counterfactual incidence rates of correctly diagnosed chlamydia 
among young women from 2000 through 2015 after correcting for individual biases (panel A) or 
sets of biases (panel B). In panel A, correcting for only reporting fraction (blue) or only 
diagnostic tests (red) resulted in counterfactual incidence rates that closely mirrored reported 
case rate trends. Correcting for coverage (green) resulted in counterfactual incidence rates that 
were substantially higher than reported case rates and relatively stable over time. In panel B, 
correcting for only reporting fraction (blue) or correcting for reporting fraction and imperfect 
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diagnostic tests (red) did not substantially alter the shape of the trends. Correcting for all three 




CHAPTER SIX: CONCLUSIONS 
 
 Valid interpretations of chlamydia prevalence and case rate trends are important for 
assessing screening program effectiveness and understanding chlamydia epidemiology on a 
national scale. Sentinel surveillance of chlamydia and national notifiable disease surveillance of 
chlamydia are convenient sources for estimating prevalence and case rates, but prevalence and 
case rate trends can be difficult to interpret due to time-varying biases. The overall goal of this 
dissertation was to estimate chlamydia prevalence and case rate trends accounting for multiple 
time-varying biases, in order to gauge the success of national screening programs at reducing 
chlamydia burden and more accurately interpret chlamydia trends from surveillance data. 
 
 We estimated minimally-biased chlamydia prevalence trends among a sentinel 
surveillance population of high-risk young adults enrolled in the NJTP. Evaluating chlamydia 
prevalence trends from sentinel surveillance allowed us to assess the success national 
chlamydia screening programs in the US, which were rolled out in the late 1980s and early 
1990s to reduce population burden. After ruling out bias due to case mix and correcting for time 
varying measurement error due to changing screening tests, chlamydia prevalence among 
women was high throughout the study period, but fell from 20% in 1990 to 12% in 2003, and 
hovered between 12% and 14% through 2012. Prevalence among men was steady throughout 
the study period at approximately 7%. For both women and men, prevalence was highest 
among Black and American Indian youth, and the Southern and Midwestern regions of the US 
throughout the study. Our trend estimates provide support for the early success of national 
chlamydia screening programs in reducing chlamydia burden among high-risk youth. The 
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relatively steady prevalence trend among women and men from 2003 through 2012 suggests 
that screening programs had no further impact for this sentinel population. 
 
 We also estimated counterfactual incidence of correctly diagnosed chlamydia among 
young women from 2000 through 2015. We corrected reported annual chlamydia case rates for 
screening- and reporting-related biases, and generated counterfactual incidence rates of 
correctly diagnosed chlamydia that would have been observed with perfect screening coverage, 
screening tests, and reporting. Counterfactual incidence rates among all young women age 15 
through 24 years were higher than reported case rates and declined over the study period from 
12,900 cases per 100,000 person-years in 2000 to 7,100 cases per 100,000 person-years in 
2015. Rates declined more sharply in the first half of the study period compared to the second. 
When stratified by age group, incidences rate trends declined relatively steadily among women 
aged through 15 through 19 years over the study period, while incidence rate trends among 
women aged 20 through 24 years declined relatively steadily until 2009 before beginning to 
stabilize. These results suggest that bias due to screening coverage, imperfect screening tests 
and reporting contribute to the rising trends of chlamydia case rates from 2000 through 2015, 
and that in the absence of biases, case rates may be declining.  
 
 Our studies are the first to thoroughly examine the influence of multiple time-varying 
biases on chlamydia prevalence and case rate trends derived from surveillance data. Our 
prevalence estimates stand apart from other estimates of prevalence in the NJTP with respect 
to duration and validity. Our study is the first to estimate prevalence among women across 23 
years and prevalence among men across 10 years. Our study is also the first to consider the 
influence of case mix and account for time-varying measurement error introduced by changes in 
screening test technologies during the study period. Long-term prevalence trends that address 
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two of the most important biases in data from sentinel surveillance programs allow us to 
consider the influence of national screening programs on chlamydia prevalence trends.  
 
 In addition, our estimation of counterfactual incidence rate of correctly diagnosed 
chlamydia cases is the first attempt to correct reported chlamydia case rates the most 
commonly discussed biases in surveillance data. Reported case rates trends are published with 
the caveat that trends are difficult to interpret due to the potential influence of biases.(1) While 
the relationship between biases and incidence rates has been examined previously,(14) our 
study is the first derive estimates the magnitude of bias due to screening coverage, screening 
tests, and under-reporting, and to correct reported case rate data for biases. Estimated 
counterfactual incidence of diagnosis trends provide a picture of what incidence trends from 
surveillance data might look like in the absence of biases. 
 
 Trends of prevalence and incidence rates of correctly diagnosed chlamydia declined but 
gradually leveled off, suggesting that although screening initially may have been effective at 
reducing chlamydia, on a population level, it may be losing momentum. Understanding why 
trends may be beginning to stabilize is important for policy makers as they consider screening 
policies and programs for the future. Our results may be evidence that screening is becoming 
less effective, but other factors that can influence trends must also be considered. Two of the 
most important factors are changes in sexual behaviors and healthcare access. Changes in 
sexual behaviors (sexual activity, condom use, and age of sexual debut) may change an 
individuals’ likelihood of becoming infected with chlamydia, and an increase in chlamydia 
prevalence and incidence would be expected with riskier sexual behaviors. Shifts in health care 
access, and changes in access to STD clinics in particular, are also important to consider. With 
budget constraints forcing state and local STD programs to close STD clinics, screening 
responsibilities shift to primary care clinics, which may be less likely than public clinics to 
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conduct routine screening. Understanding changes in sexual behaviors and changes in access 
to care in combination with screening will be important for understanding what is driving disease 
trends.  
 
 Although prevalence and counterfactual incidence rates of correctly diagnosed 
chlamydia trends were similar with respect to shape, time periods during which prevalence 
trends and incidence rates trends declined did not overlap. From 2000 through 2012, young 
women in the NJTP had a fairly small absolute increase in prevalence, while incidence rates of 
diagnosis among young women in the US declined. The differences in trends’ direction are 
potentially explained by differences in the populations giving rise to the trends. Young adults in 
the NJTP meet several important risk factors for chlamydia (low-socioeconomic status, 
predominantly Black and residing in the South, low educational attainment), and are a higher-
risk population than the total US population giving rise to incidence rates trends. Changes in 
healthcare access, possibly resulting in poorer screening of higher-risk population, could result 
in an increase in prevalence, but the change may not be substantial enough to influence 
incidence rates of diagnosis in the general population. Changes in behavior in higher-risk 
populations could also result in changes in prevalence trends that are not reflected in incidence 
rates of diagnosis trends. 
 
 Our results also highlight the need for more valid screening coverage estimates. 
Incidence rates are directly affected by screening coverage, and we observed that screening 
coverage, more so than bias from reporting and screening tests, was particularly influential on 
the shape of incidence rates of correctly diagnosed chlamydia trends. Coverage is not directly 
incorporated into estimates of prevalence, but estimation of prevalence from sentinel 
surveillance rests on an assumption that screening is sufficiently high in the underlying 
population. Accurate estimates of screening coverage are crucial for interpreting chlamydia 
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trends, but current estimates of coverage have significant limitations. Estimates from claims 
data are derived from women who present to care. (70–77) These estimates are affected by 
healthcare access and may lack generalizability because they do not capture women who seek 
care at out-of-plan facilities. Estimates from self-reported data collected by national surveys may 
be more generalizable, but may also be subject to recall bias. (78,79) Estimates from self-report 
data and estimates from claims data generally have poor concordance. (79,80) More valid 
estimates of coverage that include a denominator that is generalizable to all sexually active 
women and a well measured numerator are important for understanding whether screening 
targets are met, and for a more valid interpretation and understanding of chlamydia trends 
derived from surveillance data. 
 
 In conclusion, declining prevalence and incidence rate trends suggest that screening 
programs may have been successful in driving down population burden of chlamydia, but the 
slope of trends over time also suggest that screening may be losing momentum. Whether 
screening programs should be expanded in an attempt to drive further decline is an important 
question to consider. Policy makers will need to weigh factors that influence disease trends, 
including surveillance data biases, sexual behavior, healthcare access, and screening of men, 
as well as the cost of screening and impact of screening on reproductive sequelae and related 
outcomes. Continued surveillance of prevalence trends and case rate trends in the current era 
of highly sensitive and specific screening tests and electronic reporting will be important for 








APPENDIX 1: AIM 1 SUPPLEMENTAL METHODS 
 
Screening Test Sensitivity and Specificity Meta-Analyses 
 We searched PubMed and Scopus using medical subject headings and keywords 
related to chlamydial infection (chlamydia, sexually transmitted infection, STI, sexually 
transmitted disease, STD, urogenital, genitourinary) and diagnostic accuracy of screening tests 
(diagnostic, diagnosis, mass screening, screening, sensitivity, specificity, predictive value, 
accuracy). Studies were limited to humans and English. The last search was performed on 
March 3, 2016.  
 
 A total of 2,212 articles were initially identified. Nineteen studies were selected for 
inclusion after reviewing titles, abstracts, and full text (Appendix 1, Figure S1). Studies 
conducted outside of North America or Europe and studies of populations dissimilar to the NJTP 
(e.g. sex workers, or older/younger populations) were excluded. We included studies that 
reported the diagnostic accuracy of the Pathfinder EIA, Gen-Probe PACE 2 DNA probe, or BD 
ProbeTec ET SDA of cervical or vaginal swabs or urine. We used a standardized spreadsheet 
to abstract data. The following information was documented for each article: author(s), study 
location, study period, characteristics of sample screened (e.g. clinic patients, type of clinic, 
etc.), age, gender, sample size, specimen type, reference test definition, prevalence, sensitivity, 
specificity and potential sources of bias (e.g. discrepant analysis performed or composite 
reference test definition used). Numbers of true positives, true negatives, false positives and 










Figure A1.1: Flow diagram for study selection process for articles included in meta-analyses of 







Articles initially identified (n= 2,212) 
Articles potentially relevant for data 
abstraction (n=68) 
Eligible articles included in analyses 
(n=19) 
Articles excluded after full-text review: 
•  Wrong brand of screening test (n=22) 
•  Wrong specimen type (n=4) 
•  Population dissimilar to NJTP enrollees 
(n=9) 
•  No primary data (review, comment, 
letter) or unable to construct 2x2 table 
(n=13) 
•  Duplicate data (n=1) 
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 The relative proportion of race/ethnicity of newly enrolled women did not vary 









 The relative proportion of region (Midwest, Northeast, South, and West) did not vary 






















Figure A2.5: Adjusted and unadjusted prevalence of chlamydia among women entering the 




  Adjusted and unadjusted prevalence of chlamydia among Hispanic (n=54,799), Black 
(n=202,707), White (n=82,366), and American Indian (n=10,618) women entering the NJTP, 
1990-2012. Adjusted estimates and 95% CIs account for measurement error associated with 
changes in the diagnostic accuracy of chlamydia screening tests over time. Unadjusted 





Figure A2.6: Adjusted and unadjusted chlamydia prevalence among women entering the NJTP 




 Adjusted and unadjusted chlamydia prevalence among women entering the NJTP in four 
regions of the US, 1990-2012 (Midwest: n=64,153; South: n=157,294; West: n=68,389; 
Northeast: n=60,654). Adjusted estimates account for measurement error associated with 
changes in the diagnostic accuracy of chlamydia screening tests over time. Unadjusted 




Figure A2.7: Sensitivity analysis of adjusted chlamydia prevalence trends among women 




 Adjusted chlamydia prevalence trends among women entering the NJTP (n=350,490) 
modelled using the main sensitivity and specificity estimates for each test, as well as the upper 
and lower limits of the 95% CI around the sensitivity and specificity estimates. Adjusted 
prevalence estimates account for measurement error associated with the use of increasingly 
sensitive chlamydia screening tests over time. The unadjusted prevalence trend, which does not 
account for measurement error, is shown for comparison. 
 











  Adjusted and unadjusted chlamydia prevalence among Hispanic (n=44,822), Black 
(n=155,045), White (n=95,994), and American Indian (n=7,838) men entering the NJTP, 2003-
2012. Adjusted estimates and 95% CIs account for measurement error associated with changes 
in the diagnostic accuracy of chlamydia screening tests over time. Unadjusted estimates do not 










 Adjusted and unadjusted chlamydia prevalence among men entering the NJTP in four 
regions of the US, 2003-2012 (Midwest: n=51,361; South: n=149,464; West: n=57,144; 
Northeast: n=45,730). Adjusted estimates account for measurement error associated with 
changes in the diagnostic accuracy of chlamydia screening tests over time. Unadjusted 
estimates do not account for measurement error.  
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Figure A2.10: Sensitivity analysis of adjusted chlamydia prevalence trends among men entering 




 Adjusted chlamydia prevalence trends among men entering the NJTP (n=303,699) 
modelled using the main sensitivity and specificity estimates for each test, as well as the upper 
and lower limits of the 95% CI around the sensitivity and specificity estimates. Adjusted 
prevalence estimates account for measurement error associated with the use of increasingly 
sensitive chlamydia screening tests over time. The unadjusted prevalence trend, which does not 
account for measurement error, is shown for comparison. The unadjusted prevalence trend and 
the adjusted prevalence trend modelled using the upper sensitivity and specificity confidence 
limits follow a similar trajectory and overlap. 
 
Se = sensitivity; Sp = specificity; CL = confidence limit
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APPENDIX 3: AIM 2 SUPPLEMENTAL FIGURES 
 









 Panel A) Percentage of chlamydia screening via NAATs by ten regions of the Infertility 
Prevention Project from 2000 through 2011. Panel B) Lognormal distributions of the percentage 
of chlamydia screening via NAATs from 2000 through 2015. We created lognormal distributions 
of the percentage of screening via NAATs in an attempt to mimic the distribution of screening 
via NAATs in the Infertility Prevention Project. Distributions of the percentage of screening via 
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